Article
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.
Blood - 1 Dec 2005
Kimura Shinya, Naito Haruna, Segawa Hidekazu, Kuroda Junya, Yuasa Takeshi, Sato Kiyoshi, Yokota Asumi, Kamitsuji Yuri, Kawata Eri, Ashihara Eishi, Nakaya Yohei, Naruoka Haruna, Wakayama Tatsushi, Nasu Kimio, Asaki Tetsuo, Niwa Tomoko, Hirabayashi Kazuko, Maekawa Taira
Abstract excerpt
Although the Abelson (Abl) tyrosine kinase inhibitor imatinib mesylate has improved the treatment of breakpoint cluster region-Abl (Bcr-Abl)-positive leukemia, resistance is often reported in patients with advanced-stage disease. Although several Src inhibitors are more effective than imatinib and simultaneously inhibit Lyn, whose overexpression is associated with imatinib resistance, these inhibitors are less...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.